Sernova Achieves Positive Efficacy Endpoint in Phase I/II Clinical Trial for Type 1 Diabetes

Sernova Corp (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage company and regenerative medicine therapeutics leader, is pleased to announce that Sernova’s first treated patient in its Phase I/II clinical trial of its Cell Pouch with therapeutic cells for type 1 diabetes at the University of Chicago, has demonstrated survival of endocrine tissue (insulin-producing islets) in the sentinel Cell Pouch…

Sernova Announces Positive DSMB Review and Recommendation for Continuation of Phase I/II Diabetes Clinical Trial of Cell Pouch™

Sernova Corp (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased to announce that the independent Data Safety Monitoring Board (“DSMB”) completed its first interim analysis of the ongoing Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch™ for Clinical Islet Transplantation Phase I/II clinical trial in patients with severe hypoglycemia unawareness.…

Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial

Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes. “We are pleased to report we are on track with patient enrollment in the Sernova Cell…

Sernova-HemAcure Consortium to Present Achievements in Development of a Regenerative Medicine Approach to Treat Hemophilia A

  Sernova Corp., a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar. The webinar will include an introduction…